Monoclonal Protein Evaluation in the Diagnostic Algorithm for Cardiac Amyloidosis
LabMed · 2025
DOI: 10.3390/labmed2030013 ↗Kurz gefasst
Fachartikel in der Zeitschrift LabMed, 2025. Verfasst von Syed Bukhari. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiac amyloidosis (CA) results from the deposition of either immunoglobulin light chain (AL) or transthyretin (ATTR) amyloid fibrils in the myocardium, causing restrictive cardiomyopathy and, if left untreated, can lead to early death. Advancements in non-invasive diagnostic modalities have led to an increased recognition of the disease. Monoclonal gammopathy plays a pivotal role in the diagnostic algorithm for CA, particularly in differentiating AL from ATTR. This review highlights the importance of monoclonal protein detection through serum protein electrophoresis, immunofixation electrophoresis, and serum free light chain assays as initial screening tools. However, these tests alone are insufficient for a definitive diagnosis due to the complexities associated with coexisting monoclonal gammopathies and the potential for false negative and positive results. Advanced imaging modalities, such as echocardiography, cardiac magnetic resonance, and nuclear scintigraphy, along with tissue biopsy, are crucial for confirming CA and accurately determining the CA subtype.
Zitieren
APA
Bukhari, S. (2025). Monoclonal Protein Evaluation in the Diagnostic Algorithm for Cardiac Amyloidosis. LabMed. https://doi.org/10.3390/labmed2030013
Vancouver
Bukhari S. Monoclonal Protein Evaluation in the Diagnostic Algorithm for Cardiac Amyloidosis. LabMed. 2025. doi:10.3390/labmed2030013
BibTeX
@article{Bukhari2025,
author = {Bukhari, Syed},
title = {Monoclonal Protein Evaluation in the Diagnostic Algorithm for Cardiac Amyloidosis},
journal = {LabMed},
year = {2025},
doi = {10.3390/labmed2030013}
}
EUVIMED